Establish with the vision and determination of doctors and researchers to win over the life

threatening disease. Under the supervision of internationally acclaimed doctors and researchers
whom specializes in cancer treatment to study state of the art of cancer technology and generate
many research and development findings, Wincell is well-received by many institutions.
As leader in cancer treatment,2 sel
Wincell has develop
imun komponen utama cancer treatments
penghancur sel
under the name WinK cell, an innovative treatmentkanker, yaitu: to defeat cancer. Win-
1) Cytotoxic T Lymphocyte (CTL)
K cell is suitable for both the2)initial stage
Natural and
Killer Cellinvasion
(NK Cell) stage. With the
concept of Anti Cancer Immune Kedua Therapy by which
sel ini mampu the white
mengeluarkan zat blood cell
(lymphocyte) is make stronger to cytotoxic
kimia treat cancer yet friendly
yang mampu membentukto the patient’s
lubang penghancur pada sel kanker.
body. Pola pengaktivan CTL membutuhkan Major
Histocompatibility Complex (MHC),
sedangkan NK Cell tidak.
Win-K cell is first progress from liver cancer patients and since has been widely
accepted as international standard. In order to support this new paradigm of
treatment, National Science and Technology Development Agency and
Thailand leading medical school has selected human resources and standardize
production with cutting edge technology in order to provide a one stop services
of cancer treatments.

Win-K
cells
Therapy
Characteristics
Win-K Cell consists of 2 essential components :
1. Cytotoxic T Lymphocytes (CTL) and 2.
Cytokine induced Killer Cells (CIK) since the two
cells have different properties in destroying tumor
cells.
1. Qualification of Cytotoxic T Lymphocytes
(CTL):
CTL specifically target tumor cells (MHC
restricted pattern) by attaching its Receptor to
Tumor Antigen of the tumor cells, and releases
Cytotoxic, a chemical which has a property to
destroy tumor cells.
2. Qualification of Cytokine induced Killer Cells
(CIK): The Mechanism that activates the
destruction of tumor cells by CIK derives from
CIK recognizes the tension surrounding of tumor
cells (Tumor Microenvironment) which is
unsuitable for the normal cells to live, thus, CIK
cells can be activated by many types of tumor
cells and are not subject to any specific type of
tumor cells. It does not activated specifically to
MHC (non-majorhistocompatibility complex-
restricted). Once detected, CIK will release an
enzyme to destroy the membrane of tumor cells.
Advantages of Win-K Cell Treatment
1. Can be used with cancer patients who have been treated with surgery . WIN-K cell can
destroy remaining
 tumor cells.
2. Can be used with cancer patients who have been treated with Chemotherapy. WIN-K
can complement in
destroying tumor cell.
3. Can be used to supplement with other treatments. WIN-K cell is produced by using the
patient’s own immunity,
thus, it has no side effect to the patients or the other treatments.
4. Low rate of the cancer returning and broader time interval of cancer reoccurance.
5. Support the patient’s immunity which has been suppressed by medical or chemical and,
in turn, reduce
the rate of infection.
6. Treat patients whom cancer is present in the area where it is unable to access and
perform surgery, or cancer
has spread throughout in which surgery cannot be used to treat.
7. Reduce the number of days patient spend in the hospital because treatment only include
injection in to
the patient’s vein and so no inpatient required. Hence, reduce the cost of the patient
and the hospital.

The benefit of cultivating the immune cells with variety of cytokine is that it will multiply
the number of the immune cells. Each test the immune cells will increase 1,000 – 2,000
times which, in turn, increase the effectiveness of destroying the tumor cells, reduce the
rate of cancer recurrence and reduce the spread of tumor cells.
 Inhibition of the SK-OV-3 tumor growth by CIK cells in nude mouse xenograft models.
Irradiated nude mice (n = 5) were implanted subcutaneously with nine million SK-OV-3
ovarian cancers. CIK cells at doses from 2.3 to 9*ื107 cells/mouse were injected
intravenously each week. Adriamycin (ADR) was injected intravenously once in a week
at 2 mg/kg. Tumor volumes were estimated by the formula length (mm) ื width (mm) ื
height (mm)/2 (A). On day 28, the mice were sacrificed and the tumor weights were
measured (B and D). The body weights of the tumor bearing nude mice were measured to
estimate toxicity (C). Statistical significance was determined using the Student’s t-test
versus PBS-treated control group (*p<0.01).

CIK Cells is a cell from white blood cell (lymphocyte)- mononuclear type – which is
drawn from peripheral vessel or spleen of the animal being tested and cultivated outside the
body by giving interferon-g, CD3-antibody and interleukin-2. Cultivated CIK cells, which
express marker of natural killer cells (NK), together with T cells expressing receptor natural
killer group 2D (NKG2D). The mechanism that activates the destruction of tumor cells is
done by CIK cells detecting the tension surrounding of tumor cells (tumor
microenvironment) which is unsuitable for the normal cells to live.

CIK cells are not restricted to a specific major histocompatibility complex (MHC),
meaning , Win-K cells can be activated by many types of tumor cells and are not
subject to any specific type of tumor cells. Since CIK cells does not being activated
by a specific MHC (non-majorhistocompatibility complex-restricted). CIK cells and
tumor cells will contact and CIK cells will produce perforin to be released to destroy
cell membrane of tumor cells without the depending on eFas in stimulating the
perforin production. Additionally, it is observed that CIK cells can produce
cytokines ie. IFN-g, RANTES, MIP1a and MIP1b. Cytokines will work with IFN-g
in destroying tumor cells in the same process as T helper1 and Tcell.